1. Volume 9, Issue 9, Pages 866-872 (September 2008)
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis 
Ivana Sestak, PhD, Prof Jack Cuzick, PhD, Francisco Sapunar, MD, Prof Richard Eastell, MD, Prof John F Forbes, FRACS, Angelo R Bianco, MD, Aman U Buzdar, MD 
The Lancet Oncology 
Volume 9, Issue 9, Pages (September 2008)
DOI: /S (08)
Copyright © 2008 Elsevier Ltd Terms and Conditions

2. Figure 1
Patients (%) developing joint symptoms at or before a specified follow-up time during active treatment according to treatment first received in women without joint symptoms at entry (study population)
The Lancet Oncology 2008 9, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

3. Figure 2
Smoothed annual hazard rates (%) of newly reported joint symptoms during active treatment according to treatment first received in women without joint symptoms at entry (study population)
The Lancet Oncology 2008 9, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions